[Kadcyla® (trastuzumab emtansine) in the treatment of HER2-positive breast cancer : A rapid review]
Grati H, Jebali MC, Harzallah N, Jameleddine M
Record ID 32018011329
French
Original Title:
Kadcyla® (trastuzumab emtansine) dans le traitement du cancer du sein HER2 positif
Authors' objectives:
Clinical and economic implications of KADCYLA (trastuzumab emtansine) in the treatment of HER2+ positive breast cancer
Authors' methods:
Rapid review of literature
Details
Project Status:
Completed
Year Published:
2023
URL for published report:
https://portail.ineas.tn/Default/digital-viewer/c-1274
Requestor:
Regulatory authorities
URL for additional information:
https://portail.ineas.tn/
English language abstract:
There is no English language summary available
Publication Type:
Rapid Review
Country:
Tunisia
MeSH Terms
- Breast Neoplasms
- Trastuzumab
- Ado-Trastuzumab Emtansine
- Antineoplastic Agents, Immunological
Keywords
- "trastuzumab emtansine
- Kadcyla®
- HER2-positive breast cancer
- early stage
- locally advanced
- metastatic stage
- efficacy
- cost effectiveness"
Contact
Organisation Name:
National Authority for Assessment and Accreditation in Healthcare (INEAS)
Contact Address:
30 Rue Ibn Charaf, Tunis 1002, Tunisia
Contact Name:
Mouna Jameleddine
Contact Email:
monajameleddine@gmail.com
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.